Kala Pharmaceuticals Announces Eysuvis Now Covered by OptumRx

Kala Pharmaceuticals announced that OptumRx, one of the largest pharmacy benefit managers (PBM) in the United States, has added Eysuvis (loteprednol etabonate ophthalmic suspension) 0.25% as a covered brand on its commercial formularies, effective May 21, 2021.

“We are pleased to announce the addition of Eysuvis to OptumRx’s commercial formularies, which represents a significant milestone towards our goal of ensuring broad market access,” Todd Bazemore, Chief Operating Officer of Kala Pharmaceuticals, said in a company news release. “More than 88 million people with commercial health insurance now have access to Eysuvis. We anticipate this figure will continue to grow from our ongoing efforts with Commercial and Medicare Part D health plans, as we work towards our ultimate goal of delivering broad payer coverage for Eysuvis to the millions of people in the United States who suffer from dry eye disease.”

Eysuvis was approved by the FDA in October 2020 as the first and only prescription therapy indicated specifically for the short-term (up to 2 weeks) treatment of the signs and symptoms of dry eye disease. Kala commenced the promotional launch of Eysuvis in the United States in January 2021. Eysuvis is available through both national and regional U.S. pharmaceutical distribution centers, as well as local retail pharmacies or home delivery.